Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Scientific Advisory Board

Elizabeth P. Rakoczy, PhD
Chair

Dr. Rakoczy is the Winthrop Professor of Molecular Ophthalmology at the Lions Eye Institute, University of Western Australia, and has pioneered work in gene therapy for ocular neovascular disease.


Jean E. Bennett, MD, PhD

Dr. Bennett is the F.M. Kirby Professor of Ophthalmology at the University of Pennsylvania and is a renowned expert in gene therapy, animal models, and translational medicine in retinal disease.


Estuardo Aguilar-Cordova, MD, PhD

Dr. Aguilar-Cordova is the Chief Executive Officer, Advantagene, and a recognized expert in regulatory affairs and product development in both academic and biotechnology settings.


Mitchell H. Finer, PhD

Dr. Finer is the Chief Scientific Officer of bluebird bio and has over 25 years of experience in biotechnology product development.


J Fraser Wright, PhD

Dr. Wright is currently Director of the Clinical Vector Core at Children's Hospital of Philadelphia, and Associate Professor in Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia and University of Pennsylvania.


Daniel V. Palanker, PhD

Dr. Palanker is the Associate Professor in the Department of Ophthalmology and in Hansen Experimental Physics Laboratory at Stanford University. He is an expert in ophthalmic lasers and in interactions of pulsed electric field and light with biological cells and tissues.

Avalanche Biotechnologies Secures $55 Million in Oversubscribed Series B Financing

April 22, 2014

– Proceeds will Further Strengthen Avalanche’s Proprietary BioFactoryTM Platform and Advance Clinical Program in Wet Age-Related Macular Degeneration –


MENLO PARK, Calif., April 22, 2014 -- Avalanche Biotechnologies, Inc, a leader in the development of innovative gene therapies for serious eye diseases such as wet age-related macular degeneration (AMD), today announced the successful completion of a $55 million Series B financing. New investors were led by Venrock, and included Deerfield, Adage Capital Management, Redmile Group, Rock Springs Capital, Sabby Capital, as well as an affiliate of Cowen & Company and two undisclosed blue chip health care funds; joining the existing investors. Cowen & Company acted as sole placement agent for the financing.

Read More

Read All Avalanche News